Supernus Pharmaceuticals Files 8-K on Financials
Ticker: SUPN · Form: 8-K · Filed: Oct 21, 2025 · CIK: 1356576
| Field | Detail |
|---|---|
| Company | Supernus Pharmaceuticals, Inc. (SUPN) |
| Form Type | 8-K |
| Filed Date | Oct 21, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, financial-statements, results-of-operations
Related Tickers: SUPN
TL;DR
SUPN filed an 8-K on Oct 21, 2025, covering financial results. Details to follow.
AI Summary
On October 21, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This filing provides an update on Supernus Pharmaceuticals' financial performance and condition, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting financial results and exhibits, with no immediate indication of significant negative events.
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- October 21, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 9715 Key West Ave (address) — Principal Executive Offices
- Rockville MD 20850 (address) — Principal Executive Offices
- 301-838-2500 (phone_number) — Registrant's telephone number
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it concerns 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but the specific details are not provided in the excerpt.
When was the earliest event reported in this filing?
The earliest event reported was on October 21, 2025.
What is the principal executive office address for Supernus Pharmaceuticals, Inc.?
The principal executive office is located at 9715 Key West Ave, Rockville, MD 20850.
In which state was Supernus Pharmaceuticals, Inc. incorporated?
Supernus Pharmaceuticals, Inc. was incorporated in Delaware.
What is the telephone number for Supernus Pharmaceuticals, Inc.?
The telephone number is (301) 838-2500.
Filing Stats: 493 words · 2 min read · ~2 pages · Grade level 9.2 · Accepted 2025-10-21 17:05:17
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Sto
Filing Documents
- supn-20251021.htm (8-K) — 27KB
- ex-99110x21x2025xearningsc.htm (EX-99.1) — 12KB
- image_0.jpg (GRAPHIC) — 5KB
- 0001356576-25-000065.txt ( ) — 163KB
- supn-20251021.xsd (EX-101.SCH) — 2KB
- supn-20251021_lab.xml (EX-101.LAB) — 21KB
- supn-20251021_pre.xml (EX-101.PRE) — 12KB
- supn-20251021_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On October 21, 2025, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the third quarter of 2025 after the market closes on Tuesday, November 4, 2025. The Company will host a conference call and webcast on Tuesday, November 4, 2025 at 4:30 p.m. E.T. to discuss its third quarter 2025 financial and business results. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release dated October 2 1 , 2025 filed as an Exhibit pursuant to Item 2.02 hereof. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: October 21, 2025 By: /s/ Timothy C. Dec Timothy C. Dec Senior Vice President and Chief Financial Officer 3